CORMEDIX INC. Effective Income Tax Rate Reconciliation, Deduction, Percent
CORMEDIX INC. (CRMD) reported Effective Income Tax Rate Reconciliation, Deduction, Percent of 80.00% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationDeductions · last filed 2026-03-05
- CORMEDIX INC. effective income tax rate reconciliation, deduction, percent for fiscal 2023 was 80.00%, a 0.00% change from fiscal 2022.
- CORMEDIX INC. effective income tax rate reconciliation, deduction, percent for fiscal 2022 was 80.00%, a 0.00% change from fiscal 2021.
- CORMEDIX INC. effective income tax rate reconciliation, deduction, percent for fiscal 2021 was 80.00%, a 0.00% change from fiscal 2020.
- CORMEDIX INC. effective income tax rate reconciliation, deduction, percent for fiscal 2020 was 80.00%, a 0.00% change from fiscal 2019.
| Period end | Effective Income Tax Rate Reconciliation, Deduction, Percent | Effective Income Tax Rate Reconciliation, Deduction, Percent 12 month |
|---|---|---|
| 2023-12-31 | 80.00% 10-K · filed 2024-03-12 | |
| 2022-12-31 | 80.00% 10-K · filed 2023-03-30 | |
| 2021-12-31 | 80.00% 10-K · filed 2022-03-29 | |
| 2020-12-31 | 80.00% 10-K · filed 2021-03-30 | |
| 2019-12-31 | 80.00% 10-K · filed 2020-03-16 | |
| 2017-12-31 | 80.00% 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |